Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Marcelo C. Pasquini, MD, associate professor of medicine, Medical College of Wisconsin and senior scientific director of Center for International Blood and Marrow Transplant Research (CIBMTR) Clinical Trials Support, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
When the FDA approved the CAR T cell, the FDA mandated that the industry develop an infrastructure to follow these patients long-term as part of the approval process. There were concerns over whether these patients would develop secondary malignancies in the process of manufacturing the cells, so patients had to be followed for 15 years.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen